CENTAUR: Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Subjects With Liver Fibrosis

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 29 Dec 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cenicriviroc (Primary)
Indications Hepatic fibrosis; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
Focus Therapeutic Use
Acronyms CENTAUR
Sponsors Allergan; Tobira Therapeutics

16 Jun 2020 Results characterizing the metabolic effects of cenicriviroc (CVC), a potent CCR2/5 inhibitor, in type 2 diabetes mellitus (T2DM) patients with nonalcoholic steatohepatitis (NASH) fibrosis presented at the 80th Annual Scientific Sessions of the American Diabetes Association
13 Jan 2020 Results reporting data from the final year of the 2-year study published in the Hepatology
18 Jul 2019 According to European Clinical Trials Registry record, Canada, Israel, Moldova and Romania were in planned location.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com